|
|||||
|
|
The epidemiology of Clostridium difficile infection in patients with cancer |
|
| Authors: | Andrew I.T. Hebbard Monica A. Slavin Caroline Reed Benjamin W. Teh Karin A. Thursky Jason A. Trubiano |
| Affiliation: | 1. Department of Infectious Diseases and Infection Prevention, Peter MacCallum Cancer Centre, Melbourne, Australia;2. Department of Medicine, University of Melbourne, Melbourne, Australia;3. Microbiology Department, Peter MacCallum Cancer Centre, Melbourne, Australia |
| Abstract: | Introduction: Clostridium difficile infection (CDI) is a significant cause of healthcare-associated diarrhoea, and the emergence of endemic strains resulting in poorer outcomes is recognised worldwide. Patients with cancer are a specific high-risk group for development of infection. Areas covered: In this review, modifiable and non-modifiable risk factors for CDI in adult patients with haematological malignancy or solid tumours are evaluated. In particular, the contribution of antimicrobial exposure, hospitalisation and gastric acid suppression to risk of CDI are discussed. Recent advances in CDI treatment are outlined, namely faecal microbiota transplantation and fidaxomicin therapy for severe/refractory infection in cancer populations. Outcomes of CDI, including mortality are presented, together with the need for valid severity rating tools customised for cancer populations. Expert commentary: Future areas for research include the prognostic value of C. difficile colonisation in cancer patients and the potential impact of dedicated antimicrobial stewardship programs in reducing the burden of CDI in cancer units. |
| Keywords: | Clostridium difficile infection cancer epidemiology risks treatment outcomes |